Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00311870
Recruitment Status : Completed
First Posted : April 6, 2006
Last Update Posted : April 6, 2006
Information provided by:
Steno Diabetes Center Copenhagen

Brief Summary:
The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months

Condition or disease Intervention/treatment Phase
Diabetic Nephropathy Drug: nisoldipine Drug: lisinopril Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Study Start Date : March 1993
Study Completion Date : April 1999

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. change in glomerular filtration rate from study start to study end

Secondary Outcome Measures :
  1. blood pressure response
  2. change in urinary albumin excretion rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diabetic nephropathy, type 1 diabetes, hypertension

Exclusion Criteria:

  • child bearing potential, non-diabetic kidney disease, malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00311870

Layout table for location information
Steno Diabetes Center
Gentofte, Denmark, DK-2820
Sponsors and Collaborators
Steno Diabetes Center Copenhagen
Layout table for investigator information
Principal Investigator: Peter Rossing, MD Steno Diabetes Center Copenhagen
Study Chair: Hans-Henrik Parving, MD Steno Diabetes Center Copenhagen

Publications of Results:
Layout table for additonal information Identifier: NCT00311870    
Other Study ID Numbers: KA 92126
First Posted: April 6, 2006    Key Record Dates
Last Update Posted: April 6, 2006
Last Verified: April 1999
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Diabetic Nephropathies
Urologic Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Cardiotonic Agents
Protective Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Vasodilator Agents